DHR
Danaher Corporation
DHR's fundamentals are strong: it turned 22% of its revenue into free cash flow and earnings per share grew 26%. At 38x earnings, it's trading right at its usual valuation. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DHR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
DHR's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $232 | — |
| Cheap | 29x | $180 | -22% |
| Current | 38x | $232 | — |
| Fair | 39x | $239 | +2.8% |
| Expensive | 45x | $276 | +19% |
Historical ranges are pointers, not guarantees.
DHR's PE is in its fair range at 38x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
DHR has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.09 | +49% |
| Q3 2026 | $6.12 | +26% |
| Q2 2026 | $5.64 | +20% |
| Q1 2026 | $5.18 | +0.4% |
| Q4 2025 | $5.05 | -4.5% |
| Q3 2025 | $4.86 | -7.3% |
| Q2 2025 | $4.71 | -16% |
| Q1 2025 | $5.16 | -13% |
| Q4 2024 | $5.29 | -17% |
DHR has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.6B | +8.3% |
| Q2 2026 | $6.3B | +5.5% |
| Q1 2026 | $6B | +3.7% |
| Q4 2025 | $6.8B | +4.6% |
| Q3 2025 | $6.1B | +4.4% |
| Q2 2025 | $5.9B | +3.4% |
| Q1 2025 | $5.7B | -0.9% |
| Q4 2024 | $6.5B | +2.1% |
DHR's revenue is recovering but still below its 2022 peak: $6.6B last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -0.1 points |
| Q2 2026 | 18% | +5.2 points |
| Q1 2026 | 23% | +0.4 points |
| Q4 2025 | 22% | +0.2 points |
| Q3 2025 | 19% | +2.5 points |
| Q2 2025 | 13% | -7.5 points |
| Q1 2025 | 22% | -0.4 points |
| Q4 2024 | 22% | +0.9 points |
DHR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +19% |
| Q2 2026 | $1.3B | +16% |
| Q1 2026 | $1.1B | +2.9% |
| Q4 2025 | $1.7B | +16% |
| Q3 2025 | $1.4B | +13% |
| Q2 2025 | $1.1B | -3.5% |
| Q1 2025 | $1.1B | -27% |
| Q4 2024 | $1.5B | +24% |
DHR's free cash flow has been positive every quarter for seven years: $5.7B over the past year, up 14% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DHR on cash flow, with more consistent year-over-year improvement.
DHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -800K shares |
| 1 year | -1% | -6.9M shares |
| 3 years | -5.2% | -39.1M shares |
| 5 years | -2.8% | -20.2M shares |
| Available history | -2.6% | -18.7M shares |
DHR has 707M diluted shares, down 1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $894M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $2B |
| Q2 2025 | — |
| Q1 2025 | $1.1B |
| Q4 2024 | $809M |
DHR spent $894M buying back its own shares over the past year, down 77% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 2.9x | Moderate |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.9x | Healthy |
DHR's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.2 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.3 | Neutral |
| Stochastic | 84.4 | Overbought |
DHR's weekly RSI is 62 (neutral) and its Stochastic is 84 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DHR PE vs Healthcare Sector
| Metric | DHR | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 26x | 47% above |
| PE % | 42 | 29 | 13 pts above |
DHR is trading at 38x earnings, a 47% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $226.6 | 2.5% above |
| 20 week MA | $213.1 | 9% above |
| 50 week MA | $205.7 | 13% above |
| 100 week MA | $206.5 | 12% above |
| 200 week MA | $221.0 | 5.1% above |
DHR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.5 | $196.3 | +45% |
| 2021 | $196.3 | $284.4 | +45% |
| 2022 | $284.4 | $230.3 | -19% |
| 2023 | $230.3 | $231.3 | +0.4% |
| 2024 | $231.3 | $231.1 | -0.1% |
| 2025 | $231.1 | $230.3 | -0.3% |
| 2026 YTD | $230.3 | $232.2 | +0.8% |
DHR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.